Clinical Trial Update: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CD19 CAR T (CT032) in relapsed or refractory non-Hodgkin B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CT032 (CD19 CAR T)

Snippet

Sponsor: CARsgen Therapeutics Co., Ltd. | Conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED